IDH1 and Venetoclax in a Younger Patient Population

A lot of the clinical research offers are focusing on this patient population. Patients who have IDH1 and IDH2 who are younger, the standard of care is still 7 plus 3. We do not give these patients HMA. The reason for this is that we don't think we can cure people by giving HMA with an IDH inhibitor.